<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/04/PT-10-04-2026-image1-430x241.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="430" height="241" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/04/PT-10-04-2026-image1-430x241.jpg"/></p>
<p>根据协议，JW Pharmaceutical 获得在韩国开发和商业化 bofanglutide 的独占权。来源：Gan &amp; Lee Pharmaceuticals / PR Newswire。</p>
<p>Gan &amp; Lee Pharmaceuticals 与 JW Pharmaceutical 签署了独占许可协议，涉及在韩国进行 bofanglutide 注射的临床开发、监管审批和商业化。</p>
<p>Bofanglutide 是由 Gan &amp; Lee 发现和开发的双周给药的类胰高血糖素肽-1 受体激动剂 (GLP-1RA)。</p>
<h3>深入了解 GlobalData</h3>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>报告</p>
<h4>LOA 和 PTSR 模型 - (LAI-287 + semaglutide) 在 2 型糖尿病中的应用</h4>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>报告</p>
<h4>LOA 和 PTSR 模型 - CT-868 在肥胖症中的应用</h4>
<h5>深入了解 GlobalData</h5>
<p>商业智能的黄金标准。</p>
<p>了解更多</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>发现高效的 B2B 营销</h4>
<p>结合商业智能和编辑卓越，覆盖 36 个领先媒体平台的专业人士。</p>
<p>了解更多</p>
<p>根据协议，JW Pharmaceutical 获得开发和商业化该注射剂的独占权。</p>
<p>Gan &amp; Lee 将利用 JW Pharmaceutical 在研发方面的优势，在韩国的代谢疾病市场建立商业存在。</p>
<p>Gan &amp; Lee 将获得 500 万美元的不可退还预付款，以及高达 7610 万美元的里程碑付款，具体取决于研究、监管和商业化目标。</p>
<p>该公司还将获得净销售额的分级版税，使交易的总潜在价值达到 8110 万美元，不包括版税。</p>
<p>这是 Bofanglutide 的第三个海外授权交易，此前在印度和拉丁美洲也签署了类似协议。</p>
<p>Bofanglutide 已进入 III 期临床研究，针对肥胖/超重、2 型糖尿病和阻塞性睡眠呼吸暂停等适应症。</p>
<p>数据显示，该注射剂能够降低体重和血糖水平，同时对代谢参数产生有利影响，其安全性和耐受性与其他 GLP-1RA 疗法相似。</p>
<p>双周给药的方案将年注射次数减少了一半，相较于标准的每周一次的替代方案。</p>
<p>Gan &amp; Lee Pharmaceuticals 首席商务官 Dr Zhi Li 表示：“与 JW Pharmaceutical 的合作标志着 bofanglutide 全球化战略的又一个关键步骤。GLP-1 疗法正在重塑代谢疾病的全球治疗格局。</p>
<p>“Bofanglutide 双周给药的便利性及其显著的临床益处将有助于满足韩国患者未被满足的医疗需求。JW 拥有超过 80 年的经验，在代谢疾病领域具备深厚的开发和商业专业知识，这是我们选择与 JW 合作的关键因素。”</p>

甘李药业

<p>甘李药业已与 JW Pharmaceutical 签署独家许可协议，以在韩国商业化博方鲁肽注射液。JW Pharmaceutical 将开发和商业化该药物，获得 500 万美元的预付款以及总计 7610 万美元的潜在里程碑付款。博方鲁肽是一种每两周一次的 GLP-1 受体激动剂，目前正在进行针对肥胖、2 型糖尿病和睡眠呼吸暂停的第三阶段临床试验。此次合作旨在利用 JW 在代谢疾病市场的专业知识，提升韩国的患者护理</p>

<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/04/PT-10-04-2026-image1-430x241.jpg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/04/PT-10-04-2026-image1-430x241.jpg"/></p>
<p>Under the agreement, JW Pharmaceutical gains exclusive rights to develop and commercialise bofanglutide in South Korea. Credit: Gan &amp; Lee Pharmaceuticals / PR Newswire.</p>
<div class="lb-trans"><p>根据协议，JW Pharmaceutical 获得在韩国开发和商业化 bofanglutide 的独占权。来源：Gan &amp; Lee Pharmaceuticals / PR Newswire。</p>
</div><p>Gan &amp; Lee Pharmaceuticals has entered an exclusive licence agreement with JW Pharmaceutical for the clinical development, regulatory approval, and commercialisation of bofanglutide injection in South Korea.</p>
<div class="lb-trans"><p>Gan &amp; Lee Pharmaceuticals 与 JW Pharmaceutical 签署了独占许可协议，涉及在韩国进行 bofanglutide 注射的临床开发、监管审批和商业化。</p>
</div><p>Bofanglutide is a bi-weekly glucagon-like peptide-1 receptor agonist (GLP-1RA) discovered and developed by Gan &amp; Lee.</p>
<div class="lb-trans"><p>Bofanglutide 是由 Gan &amp; Lee 发现和开发的双周给药的类胰高血糖素肽-1 受体激动剂 (GLP-1RA)。</p>
</div><h3>Go deeper with GlobalData</h3>
<div class="lb-trans"><h3>深入了解 GlobalData</h3>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>报告</p>
</div><h4>LOA and PTSR Model - (LAI-287 + semaglutide) in Type 2 Diabetes</h4>
<div class="lb-trans"><h4>LOA 和 PTSR 模型 - (LAI-287 + semaglutide) 在 2 型糖尿病中的应用</h4>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>报告</p>
</div><h4>LOA and PTSR Model - CT-868 in Obesity</h4>
<div class="lb-trans"><h4>LOA 和 PTSR 模型 - CT-868 在肥胖症中的应用</h4>
</div><h5>Go deeper with GlobalData</h5>
<div class="lb-trans"><h5>深入了解 GlobalData</h5>
</div><p>The gold standard of business intelligence.</p>
<div class="lb-trans"><p>商业智能的黄金标准。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>了解更多</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>Discover B2B Marketing That Performs</h4>
<div class="lb-trans"><h4>发现高效的 B2B 营销</h4>
</div><p>Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.</p>
<div class="lb-trans"><p>结合商业智能和编辑卓越，覆盖 36 个领先媒体平台的专业人士。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>了解更多</p>
</div><p>Under the agreement, JW Pharmaceutical gains exclusive rights to develop and commercialise the injection.</p>
<div class="lb-trans"><p>根据协议，JW Pharmaceutical 获得开发和商业化该注射剂的独占权。</p>
</div><p>Gan &amp; Lee will leverage the strengths of JW Pharmaceutical in R&amp;D to establish a commercial presence in South Korea’s metabolic disease market.</p>
<div class="lb-trans"><p>Gan &amp; Lee 将利用 JW Pharmaceutical 在研发方面的优势，在韩国的代谢疾病市场建立商业存在。</p>
</div><p>Gan &amp; Lee will receive a non-refundable upfront payment of $5m, with milestone payments up to $76.1m, dependent on research, regulatory, and commercialisation targets.</p>
<div class="lb-trans"><p>Gan &amp; Lee 将获得 500 万美元的不可退还预付款，以及高达 7610 万美元的里程碑付款，具体取决于研究、监管和商业化目标。</p>
</div><p>The company will also obtain tiered royalties on net sales, bringing the total potential transaction value to $81.1m, excluding royalties.</p>
<div class="lb-trans"><p>该公司还将获得净销售额的分级版税，使交易的总潜在价值达到 8110 万美元，不包括版税。</p>
</div><p>This marks the third overseas out-licensing deal for Bofanglutide, after similar agreements in India and Latin America.</p>
<div class="lb-trans"><p>这是 Bofanglutide 的第三个海外授权交易，此前在印度和拉丁美洲也签署了类似协议。</p>
</div><p>Bofanglutide has entered Phase III clinical research, targeting indications such as obesity/overweight, type 2 diabetes mellitus, and obstructive sleep apnoea.</p>
<div class="lb-trans"><p>Bofanglutide 已进入 III 期临床研究，针对肥胖/超重、2 型糖尿病和阻塞性睡眠呼吸暂停等适应症。</p>
</div><p>Data indicate that the injection reduces body weight and blood glucose levels while favourably affecting metabolic parameters, with a safety and tolerability profile similar to other GLP-1RA therapies.</p>
<div class="lb-trans"><p>数据显示，该注射剂能够降低体重和血糖水平，同时对代谢参数产生有利影响，其安全性和耐受性与其他 GLP-1RA 疗法相似。</p>
</div><p>The bi-weekly dosing schedule minimises the annual number of injections by half compared to the standard once-weekly alternatives.</p>
<div class="lb-trans"><p>双周给药的方案将年注射次数减少了一半，相较于标准的每周一次的替代方案。</p>
</div><p>Gan &amp; Lee Pharmaceuticals chief business officer Dr Zhi Li said: “This partnership with JW Pharmaceutical marks another pivotal step in the globalisation strategy for bofanglutide. GLP-1 therapies are reshaping the global treatment landscape for metabolic diseases.</p>
<div class="lb-trans"><p>Gan &amp; Lee Pharmaceuticals 首席商务官 Dr Zhi Li 表示：“与 JW Pharmaceutical 的合作标志着 bofanglutide 全球化战略的又一个关键步骤。GLP-1 疗法正在重塑代谢疾病的全球治疗格局。</p>
</div><p>“The convenience of Bofanglutide’s bi-weekly dosing and its compelling clinical benefits will help address the unmet medical needs of South Korean patients. With over 80 years of experience, JW brings deep development and commercial expertise in metabolic diseases—a key factor in our decision to partner with JW.”</p>
<div class="lb-trans"><p>“Bofanglutide 双周给药的便利性及其显著的临床益处将有助于满足韩国患者未被满足的医疗需求。JW 拥有超过 80 年的经验，在代谢疾病领域具备深厚的开发和商业专业知识，这是我们选择与 JW 合作的关键因素。”</p>
</div>

甘李药业与 JW 制药达成博方鲁肽商业化协议